Once operational in 2025 (subject to regulatory approval), the facility will produce up to 100 million vaccine doses annually for respiratory diseases including influenza, RSV, and COVID-19, while creating hundreds of jobs across the advanced medical manufacturing sector.

Led by partners, Owen Cooper and Sian Keast, the team included Special Counsel, Tim Mitchell, and senior associates, associates, and specialists from various practice areas.

Owen Cooper, Partner at MinterEllison, said: "We are delighted to have partnered with Moderna on this landmark project. This facility will not only enhance Australia’s sovereign capability in mRNA manufacturing but also deliver substantial economic and healthcare benefits for the nation."

Sian Keast, Partner at MinterEllison, said: "This project underscores the firm's commitment to life sciences innovation and our support for groundbreaking work that enhances Australia's health and economic landscape.”

MinterEllison’s involvement reflects the firm’s deep expertise in advising on complex infrastructure projects in the health and life sciences sector, helping clients navigate critical legal and strategic considerations to advance innovative scientific solutions.